Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis

By H. Kong, Julia Oh, C. Deming, Sean Conlan, Elizabeth A. Grice, Melony A. Beatson, Effie Y. H. Nomicos, E. Polley, Hirsh D. Komarow, P. Murray and 2 more. Genome Research, 2012

1,622 citations recorded by the source corpus.

Atopic dermatitis (AD) has long been associated with Staphylococcus aureus skin colonization or infection and is typically managed with regimens that include antimicrobial therapies. However, the role of microbial communities in the pathogenesis of AD is incompletely characterized. To assess the relationship between skin microbiota and disease progression, 16S ribosomal RNA bacterial gene sequencing was performed on DNA obtained directly from serial skin sampling of children with AD. The composition of bacterial communities was analyzed during AD disease states to identify characteristics associated with AD flares and improvement post-treatment. We found that microbial community structures at sites of disease predilection were dramatically different in AD patients compared with controls. Microbial diversity during AD flares was dependent on the presence or absence of recent AD treatments, with even intermittent treatment linked to greater bacterial diversity than no recent treatment. Treatment-associated changes in skin bacterial diversity suggest that AD treatments diversify skin bacteria preceding improvements in disease activity. In AD, the proportion of Staphylococcus sequences, particularly S. aureus, was greater during disease flares than at baseline or post-treatment, and correlated with worsened disease severity. Representation of the skin commensal S. epidermidis also significantly increased during flares. Increases in Streptococcus, Propionibacterium, and Corynebacterium species were observed following therapy. These findings reveal linkages between microbial communities and inflammatory diseases such as AD, and demonstrate that as compared with culture-based studies, higher resolution examination of microbiota associated with human disease provides novel insights into global shifts of bacteria relevant to disease progression and treatment.

Subfields: Dermatology, Immunology and Allergy, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/53b773d978d49941c56802a352edbbe32f241bd4

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Dermatology

In Molecular Biology

Citations in the corpus

Consensus‐based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I (2018, background): “14 Super potent TCS (group IV) are not recommended for AE treatment, especially not in 15 children (3).”
Temporal Stability of the Human Skin Microbiome (2016, positive): “Intrinsic conditions like immunosuppression, illness, or the occurrence of disease have also been shown to cause major shifts in skin communities (Kong et al., 2012; Oh et al., 2013).”
The human microbiome (2017, background): “characterized by increased colonization of Staphylococcus aureus and decreased bacterial diversity [53].”
Role of the Microbiota in Immunity and inflammation (2014, background): “Nonetheless and despite the growing number of studies that associate commensal dysbiosis at diverse tissue sites with specific pathologies such as psoriasis, atopic dermatitis and asthma, (Abreu et al., 2012; Belda-Ferre et al., 2012; Hilty et al., 2010; Kong et al., 2012; Srinivasan et al., 2010) l”